PROTEOSUITE Trademark

Trademark Overview

On Monday, March 27, 2023, a trademark application was filed for PROTEOSUITE with the United States Patent and Trademark Office. The USPTO has given the PROTEOSUITE trademark a serial number of 97858744. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, March 19, 2024. This trademark is owned by CATALENT PHARMA SOLUTIONS, INC.. The PROTEOSUITE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of pharmaceutical research, namely, conducting pharmaceutical product developability assessments for protein degraders to identify orally bioavailable pharmaceutical candidates; Research and development in the field of oral drug formulations and drug dosage; Scientific and technological services, namely, scientific research, analysis, screening and testing in the field of oral drug formulation development; Research and development in the field of protein degrader drugs; Research and development in the field of small molecule therapeutics; Conducting scientific feasibility studies; Pharmaceutical research services; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical products development; Pharmaceutical drug development services
proteosuite

General Information

Serial Number97858744
Word MarkPROTEOSUITE
Filing DateMonday, March 27, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, March 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 23, 2024

Trademark Statements

Goods and ServicesResearch and development in the field of pharmaceutical research, namely, conducting pharmaceutical product developability assessments for protein degraders to identify orally bioavailable pharmaceutical candidates; Research and development in the field of oral drug formulations and drug dosage; Scientific and technological services, namely, scientific research, analysis, screening and testing in the field of oral drug formulation development; Research and development in the field of protein degrader drugs; Research and development in the field of small molecule therapeutics; Conducting scientific feasibility studies; Pharmaceutical research services; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical products development; Pharmaceutical drug development services

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, April 18, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCATALENT PHARMA SOLUTIONS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSomerset, NJ 08873
Party NameCATALENT PHARMA SOLUTIONS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSomerset, NJ 08873

Trademark Events

Event DateEvent Description
Thursday, March 30, 2023NEW APPLICATION ENTERED
Wednesday, January 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, December 20, 2023ASSIGNED TO EXAMINER
Thursday, December 21, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 19, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 17, 2024TEAS STATEMENT OF USE RECEIVED

Related Keywords

proteosuite development research pharmaceutical field drug scientific services protein conducting namely